---
title: "Neonc Tech | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286819054.md"
datetime: "2026-05-18T21:02:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286819054.md)
  - [en](https://longbridge.com/en/news/286819054.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286819054.md)
---

# Neonc Tech | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.38.

#### Financial Results for Q1 2026

-   **General & Administrative (G&A) Expenses**: NeOnc Technologies Holdings, Inc.’s G&A expenses were $488,709 for the first quarter of 2026, a decrease from $849,485 in Q1 2025, primarily due to reduced marketing, rent, travel, and Middle East partnership-related costs in 2026.
-   **Research & Development (R&D) Expenses**: R&D expenses for the first quarter of 2026 were $1,286,336, an increase from $998,222 in Q1 2025, driven by active management of NEO100 trial sites, recruitment for NEO212, initiation of the NEO100-3 study, and overall patient recruitment activity.
-   **Net Loss**: The net loss for Q1 2026 was -$8.8 million, or -$0.38 per diluted share, an improvement compared to -$32.3 million, or -$1.78 per diluted share, in Q1 2025, reflecting a significant reduction in non-cash stock-based compensation and listing-related advisory fees recognized in Q1 2025.
-   **Non-cash Stock-based Compensation**: Approximately $2.7 million of the Q1 2026 net loss reflects non-cash stock-based compensation.
-   **Normalized Cash Operating Expenses (Non-GAAP)**: Normalized cash operating expenses (Non-GAAP) were -$6,087,535 for the first quarter of 2026, which annualizes to approximately -$24.4 million.

#### Cash Position and Capital

-   **Cash and Cash Equivalents**: As of March 31, 2026, cash and cash equivalents were $138,601.
-   **PIPE Financing**: NeOnc Technologies Holdings, Inc. raised a PIPE investment anchored by a $10 million commitment from Cinctive Capital Management.
-   **Undrawn Line of Credit**: The company maintains a $10 million undrawn line of credit.
-   **Funding Runway**: The company’s cash and cash equivalents, along with the PIPE proceeds and undrawn line of credit, are expected to fund planned operations into September 2026.

#### Operational Highlights

-   **NEO212 Clinical Progress**: The Phase 1 dose-escalation portion for NEO212 was successfully completed, establishing 610 mg as the recommended Phase 2 dose, with early signs of clinical activity and potential durable disease stabilization observed in heavily pretreated recurrent GBM and brain metastasis patients.
-   **NEO100 Clinical Progress**: The Phase 2a study for NEO100 in recurrent IDH1-mutant high-grade glioma is fully enrolled, with previously reported results including a 24% radiographic remission rate, 44% six-month progression-free survival, and an absence of significant toxicity.
-   **Leadership Appointment**: David Choi was appointed as Chief Accounting Officer.

#### Outlook / Guidance

NeOnc Technologies Holdings, Inc. plans to request a Type B End-of-Phase 1 meeting with the FDA for NEO212 to align on the design of a potentially pivotal registrational Phase 2 study and evaluate potential pathways toward accelerated regulatory review. For NEO100, an interim data readout from the fully enrolled Phase 2a study is anticipated later this year, expected in approximately August 2026. The company’s current financial resources, including a PIPE financing and an undrawn line of credit, are projected to fund planned operations into September 2026.

### Related Stocks

- [NTHI.US](https://longbridge.com/en/quote/NTHI.US.md)

## Related News & Research

- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)
- [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)